Agreed, don't think it would help CRM business but St Jude and Boston didn't have any type of spine background or partnership in their portfolios before they jumped into the neuromodulation business.
True, but the real game changer will be the bio-absorbable stent...outlook is for BIO to be first or second to market...regardless it will garner some attention and legitimacy....